Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MSRA Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA582845
Description
Immunogen sequence: ASNIVSPQEA LPGRKEQTPV AAKHHVNGNR TVEPFPEGTQ MAVFGMGCFW GAERKFWVLK GVYSTQVG.
Methionine sulfoxide reductase (MsrA) reduces methionine sulfoxide (MetO) residues in proteins and free MetO to Methionine (Met). The catalytic activity of MsrA is dependent of bound metal and cofactors but it requires reducing equivalents from either DTT or a thioredoxin-regenerating system. MsrA plays an essential role in protecting cells against oxidative damage. The substrates of MsrA include calmodulin, HIV protease and a 1-proteinase-inhibitor. Recent studies indicate that there is a connection between MsrA and Alzheimer's disease in mammals.
Specifications
MSRA | |
Polyclonal | |
Unconjugated | |
Msra | |
2310045J23Rik; 6530413P12Rik; cytosolic methionine-S-sulfoxide reductase; methionine sulfoxide reductase A; mitochondrial peptide methionine sulfoxide reductase; Msra; MSR-A; peptide met (O) reductase; peptide Met(O) reductase; peptide methionine sulfoxide reductase; peptide-methionine (S)-S-oxide reductase; PMSR; protein-methionine-S-oxide reductase | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
4482 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
0.10 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9UJ68 | |
Msra | |
Recombinant protein corresponding to Human MSRA. Recombinant protein control fragment (Product #RP-93911). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction